Ketoconazole - Warnings and Precautions

WARNINGS Because of the serious adverse reactions that have been reported in association with ketoconazole, including fatal hepatotoxicity, ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections.

Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks.

Hepatotoxicity Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation, has occurred with the use of oral ketoconazole.

Some patients had no obvious risk factors for liver disease.

Serious hepatotoxicity was reported both by patients receiving high doses for short treatment durations and by patients receiving low doses for long durations.

The hepatic injury has usually, but not always, been reversible upon discontinuation of ketoconazole treatment.

Cases of hepatitis have been reported in children.

At baseline, obtain laboratory tests (such as SGGT, alkaline phosphatase, ALT, AST, total bilirubin (TBL), Prothrombin Time (PT), International Normalization Ratio (INR), and testing for viral hepatitides).

Patients should be advised against alcohol consumption while on treatment.

If possible, use of other potentially hepatotoxic drugs should be avoided in patients receiving ketoconazole tablets.

Prompt recognition of liver injury is essential.

During the course of treatment, serum ALT should be monitored weekly for the duration of treatment.

If ALT values increase to a level above the upper limit of normal or 30 percent above baseline, or if the patient develops symptoms, ketoconazole treatment should be interrupted and a full set of liver tests should be obtained.

Liver tests should be repeated to ensure normalization of values.

Hepatotoxicity has been reported with restarting oral ketoconazole (rechallenge).

If it is decided to restart oral ketoconazole, monitor the patient frequently to detect any recurring liver injury from the drug.

QT Prolongation and Drug Interactions Leading to QT Prolongation Ketoconazole con prolong the QT interval.

Co-administration of the following drugs with ketoconazole is contraindicated: dofetilide, quinidine, pimozide, lurasidone,cisapride, methadone, disopyramide, dronedarone, ranolazine.

Ketoconazole can cause elevated plasma concentrations of these drugs which may prolong the QT interval, sometimes resulting in life-threatening ventricular dysrhythmias such as torsades de pointes.

Adrenal Insufficiency Ketoconazole tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher.

This effect is not shared with other azoles.

The recommended dose pf 200 mg to 400 mg daily should not be exceeded.

Adrenal function should be monitored in patients with adrenal insufficiency or with borderline adrenal function and in patients under prolonged periods of stress (major surgery, intensive care, etc.).

Adverse Reactions Associated with Unapproved Uses Ketoconazole has been used in high doses for the treatment of advanced prostate cancer and for Cushing's syndrome when other treatment options have failed.

The safety and effectiveness of ketoconazole have not been established in these settings and the use of ketoconazole for these indications is not approved by FDA.